Kentucky

presented by
Daily

Immunotherapy player Apellis Pharmaceuticals raises $33M

Apellis Pharmaceuticals just raised $33M to fund exploring its immunotherapy platform in three disparate indications – disease of the bone marrow, the lungs and the eye. The round, which is a private placement of its Series C preferred stock, was led by Morningside Ventures, AJU IB Investment Co. and Epidarex Ventures. The indications are: -Paroxysmal nocturnal hemoglobinuria, […]